APO-RIVASTIGMINE rivastigmine (as hydrogen tartrate) 3mg capsule bottle

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

rivastigmine hydrogen tartrate, Quantity: 4.8 mg

Disponibbli minn:

Arrotex Pharmaceuticals Pty Ltd

INN (Isem Internazzjonali):

rivastigmine hydrogen tartrate

Għamla farmaċewtika:

Capsule

Kompożizzjoni:

Excipient Ingredients: titanium dioxide; microcrystalline cellulose; Gelatin; maize starch; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

56, 500, 100

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

Rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the Alzheimer's type

Sommarju tal-prodott:

Visual Identification: Hard gelatine calsule with orange, opaque body and orange opaque cap. Imprinted "APO R3" in black ink, white to off white fill.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

2010-07-27